

SENESCO TECHNOLOGIES INC

Form 8-K

August 29, 2014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): August 29, 2014

Senesco Technologies, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

(State or Other Jurisdiction  
of Incorporation)

001-31326

(Commission File Number) (IRS Employer Identification No.)

84-1368850

Edgar Filing: SENESCO TECHNOLOGIES INC - Form 8-K

721 Route 202-206, Suite 130, Bridgewater, NJ 08807  
(Address of Principal Executive Offices) (Zip Code)

(908) 864-4444  
(Registrant's telephone number,  
including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

**Item 8.01 Other Events.**

On August 29, 2014, Senesco Technologies, Inc. (the “Company”) issued a press release announcing that the Phase 1 dose escalation stage of the Company’s Phase 1b/2a clinical study of its lead product candidate for the potential treatment of multiple myeloma, plasma cell leukemia or B cell lymphoma, SNS01-T, has now established a maximum tolerated dose following the reporting of a second dose limiting toxicity in the fourth dosing cohort. Pursuant to the study protocol, the trial will stop recruitment and all patients currently enrolled at reduced doses will be monitored through study completion.

A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

Exhibit No.   Description

99.1            Press Release of Senesco Technologies, Inc. dated August 29, 2014.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**SENESCO  
TECHNOLOGIES, INC.**

Dated: August 29, 2014 By: /s/ Ronald Martell  
Name: Ronald Martell  
Title: Chief Executive Officer